Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolic Profile of Bemcentinib in Healthy Males
NCT06469138Phase 1Completed
- Sponsor
- BerGenBio ASA
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemcentinib in non-small cell lung cancer (NSCLC), melanoma, acute myeloid leukemia (AML) and 4 more, sponsored by BerGenBio ASA. Primary endpoints: Total Radioactivity - Plasma Maximum Observed Concentration at 2 weeks, Total Radioactivity - Whole Blood Maximum Observed Concentration at 2 weeks and 5 more. Started Aug 2022; status: completed.
02
Drugs
bemcentinib
03
Conditions
non-small cell lung cancer (NSCLC)melanomaacute myeloid leukemia (AML)myelodysplastic syndromes (MDS)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06469138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469138.